For the second consecutive year, Quintiles has been named Best Clinical Research Organization (CRO) in the Vaccine Industry Excellence (ViE) Awards. Presented at the World Vaccine Congress now under way in Washington, D.C., the awards recognize and celebrate individuals, organizations and initiatives which have made significant contributions over the past 12 months.
The Best CRO award is presented to the honored CRO following two rounds of evaluation. First, customers vote for their preferred CRO online prior to the World Vaccine Congress to arrive at a list of five companies per category. Then, a judging panel makes its selection based on information provided in the following criteria:
“We’re proud to be recognized by our customers and peers as the Best CRO,” said Dr. Christopher Cabell, senior vice president, Therapeutic Delivery Unit. “We work every day to advance the development of quality vaccines and anti-infective products. This achievement celebrates our commitment to create a healthier world.”
Two Quintiles scientific and operational experts presented as part of the technical seminars offered at the World Vaccine Congress.
Quintiles helped develop or commercialize 73% (11 of 15) of 2011’s best selling Vaccine products or compounds.
For more news on vaccines in clinical trials, check out the edition of ACT Direct e-news that went out this morning.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.